Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.08
NYSE:MNK's Cash to Debt is ranked lower than
93% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. NYSE:MNK: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MNK' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.21 Max: N/A
Current: 0.08
Equity to Asset 0.33
NYSE:MNK's Equity to Asset is ranked lower than
86% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.65 vs. NYSE:MNK: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MNK' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.35 Max: 0.41
Current: 0.33
0.25
0.41
Interest Coverage 1.81
NYSE:MNK's Interest Coverage is ranked lower than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.40 vs. NYSE:MNK: 1.81 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MNK' s Interest Coverage Range Over the Past 10 Years
Min: 1.81  Med: 202.47 Max: 470.4
Current: 1.81
1.81
470.4
F-Score: 6
Z-Score: 0.82
M-Score: -2.75
WACC vs ROIC
11.29%
10.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.07
NYSE:MNK's Operating margin (%) is ranked higher than
78% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. NYSE:MNK: 18.07 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MNK' s Operating margin (%) Range Over the Past 10 Years
Min: -3.65  Med: 11.44 Max: 18.07
Current: 18.07
-3.65
18.07
Net-margin (%) 16.38
NYSE:MNK's Net-margin (%) is ranked higher than
82% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.71 vs. NYSE:MNK: 16.38 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MNK' s Net-margin (%) Range Over the Past 10 Years
Min: -15.34  Med: 6.55 Max: 16.38
Current: 16.38
-15.34
16.38
ROE (%) 11.61
NYSE:MNK's ROE (%) is ranked higher than
66% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.47 vs. NYSE:MNK: 11.61 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MNK' s ROE (%) Range Over the Past 10 Years
Min: -10.28  Med: 6.32 Max: 11.61
Current: 11.61
-10.28
11.61
ROA (%) 3.82
NYSE:MNK's ROA (%) is ranked higher than
53% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. NYSE:MNK: 3.82 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MNK' s ROA (%) Range Over the Past 10 Years
Min: -3.91  Med: 2.22 Max: 3.82
Current: 3.82
-3.91
3.82
ROC (Joel Greenblatt) (%) 48.41
NYSE:MNK's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. NYSE:MNK: 48.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4.96  Med: 9.97 Max: 48.41
Current: 48.41
-4.96
48.41
» NYSE:MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNK Guru Trades in Q4 2015

Mario Gabelli 15,562 sh (New)
Jeremy Grantham 3,834 sh (New)
Ken Heebner 665,000 sh (New)
David Dreman 203 sh (New)
Louis Moore Bacon 16,998 sh (New)
Paul Tudor Jones 8,097 sh (New)
George Soros 6,500 sh (New)
John Paulson 8,623,693 sh (+30.78%)
First Eagle Investment 187 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Pioneer Investments Sold Out
» More
Q1 2016

MNK Guru Trades in Q1 2016

Joel Greenblatt 580,887 sh (New)
David Dreman 4,027 sh (+1883.74%)
Ken Heebner 1,125,000 sh (+69.17%)
John Paulson 8,949,380 sh (+3.78%)
First Eagle Investment 187 sh (unchged)
Jeremy Grantham Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Paul Tudor Jones 7,622 sh (-5.87%)
Mario Gabelli 14,562 sh (-6.43%)
» More
Q2 2016

MNK Guru Trades in Q2 2016

Steven Cohen 120,400 sh (New)
David Dreman 4,448 sh (+10.45%)
First Eagle Investment 187 sh (unchged)
Mario Gabelli 14,562 sh (unchged)
John Paulson 8,371,080 sh (-6.46%)
Ken Heebner 1,014,000 sh (-9.87%)
Paul Tudor Jones 5,434 sh (-28.71%)
Joel Greenblatt 246,825 sh (-57.51%)
» More
Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:OPK, NYSE:VRX, OTCPK:IPSEY, OTCPK:HYPMY, OTCPK:HLUYY, OTCPK:HKMPF, OTCPK:SFOSF, NYSE:RDY, NYSE:TARO, NAS:NBIX, NYSE:PTHN, NAS:ENDP, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, NAS:AKRX, OTCPK:APNHY, NAS:MDCO, NAS:IRWD, NAS:RDUS » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents.

Mallinckrodt PLC was incorporated in Ireland on January 9, 2013. The Company along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Its therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. It also supports the diagnosis of disease with nuclear medicine imaging agents. The Company operates in three segments including Specialty Brands, Specialty Generics, and Nuclear Imaging. Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals products for autoimmune and rare diseases (including in the specialty areas of neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; and central nervous system drugs. Its Specialty Brands product portfolio includes Acthar an injectable biopharmaceutical drug; Ofirmev a proprietary intravenous formulation of acetaminophen indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever; Inomax a vasodilator that, in conjunction with ventilatory support and other appropriate agents, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension; Therakos immunotherapy provides immunotherapy treatment platforms that enhance the ability of a patient's immune system to fight disease; and Exalgo a long-acting, once-daily form of hydromorphone. Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Specialty Generics product portfolio includes hydrocodone (API) and hydrocodone-containing tablets; hydrocodone (API) and hydrocodone-containing tablets; methylphenidate HCl extended-release tablets USP (CII); and other controlled substances, including acetaminophen (API) products. Nuclear Imaging segment develops, manufactures and markets products which provide radiopharmaceuticals used in single photon emission computed tomography ("SPECT") imaging for myocardial perfusion, cardiac imaging and bone scans. Its Nuclear Imaging business manufactures radioactive isotopes for the diagnosis and treatment of disease. Its nuclear radiopharmaceutical product offering includes both hot radioisotopes and cold kits. The Nuclear Imaging product portfolio includes Ultra-Technekow DTE a dry-ship, top

Ratios

vs
industry
vs
history
P/E(ttm) 9.63
MNK's P/E(ttm) is ranked higher than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.64 vs. MNK: 9.63 )
Ranked among companies with meaningful P/E(ttm) only.
MNK' s P/E(ttm) Range Over the Past 10 Years
Min: 9.36  Med: 29.75 Max: 73.31
Current: 9.63
9.36
73.31
Forward P/E 6.44
MNK's Forward P/E is ranked higher than
94% of the 94 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.71 vs. MNK: 6.44 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 11.13
MNK's PE(NRI) is ranked higher than
86% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.23 vs. MNK: 11.13 )
Ranked among companies with meaningful PE(NRI) only.
MNK' s PE(NRI) Range Over the Past 10 Years
Min: 10.78  Med: 31.46 Max: 416.74
Current: 11.13
10.78
416.74
P/B 1.07
MNK's P/B is ranked higher than
84% of the 953 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MNK: 1.07 )
Ranked among companies with meaningful P/B only.
MNK' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 2.15 Max: 3.59
Current: 1.07
1.03
3.59
P/S 1.54
MNK's P/S is ranked higher than
69% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.91 vs. MNK: 1.54 )
Ranked among companies with meaningful P/S only.
MNK' s P/S Range Over the Past 10 Years
Min: 1.11  Med: 2.32 Max: 4.82
Current: 1.54
1.11
4.82
POCF 4.40
MNK's POCF is ranked higher than
89% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.38 vs. MNK: 4.40 )
Ranked among companies with meaningful POCF only.
MNK' s POCF Range Over the Past 10 Years
Min: 4.28  Med: 14.01 Max: 45.78
Current: 4.4
4.28
45.78
EV-to-EBIT 17.03
MNK's EV-to-EBIT is ranked higher than
56% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.57 vs. MNK: 17.03 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -919.8  Med: 28.2 Max: 241.3
Current: 17.03
-919.8
241.3
EV-to-EBITDA 7.67
MNK's EV-to-EBITDA is ranked higher than
83% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. MNK: 7.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.55  Med: 15.6 Max: 45.1
Current: 7.67
7.55
45.1
Current Ratio 1.68
MNK's Current Ratio is ranked lower than
68% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. MNK: 1.68 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 2.31 Max: 2.86
Current: 1.68
1.68
2.86
Quick Ratio 1.31
MNK's Quick Ratio is ranked lower than
66% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MNK: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 1.31  Med: 1.68 Max: 2.41
Current: 1.31
1.31
2.41
Days Inventory 72.49
MNK's Days Inventory is ranked higher than
74% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.87 vs. MNK: 72.49 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.89  Med: 82.66 Max: 126.72
Current: 72.49
71.89
126.72
Days Sales Outstanding 49.51
MNK's Days Sales Outstanding is ranked higher than
73% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.59 vs. MNK: 49.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.51  Med: 83.55 Max: 85.44
Current: 49.51
49.51
85.44
Days Payable 27.07
MNK's Days Payable is ranked lower than
88% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.65 vs. MNK: 27.07 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 27.07  Med: 39.54 Max: 49.58
Current: 27.07
27.07
49.58

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.71
MNK's Price/Median PS Value is ranked higher than
82% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MNK: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
MNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 0.96 Max: 1.94
Current: 0.71
0.52
1.94
Earnings Yield (Greenblatt) (%) 5.90
MNK's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 1015 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. MNK: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 3 Max: 6.01
Current: 5.9
0.4
6.01

More Statistics

Revenue (TTM) (Mil) $3,686
EPS (TTM) $ 5.34
Beta1.88
Short Percentage of Float7.53%
52-Week Range $50.90 - 85.83
Shares Outstanding (Mil)105.86

Analyst Estimate

Sep16 Sep17 Sep18 Sep19
Revenue (Mil $) 3,395 3,403 3,470 3,592
EPS ($) 7.44 7.80 8.50 8.95
EPS w/o NRI ($) 7.44 7.80 8.50 8.95
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:MNK

Headlines

Articles On GuruFocus.com
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
10 Stocks David Dreman Is Buying Sep 21 2016 
Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Pioneer Investments Adds to Stakes in Hartford Financial Group, Reynolds American Nov 13 2015 
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 

More From Other Websites
MALLINCKRODT PLC Financials Dec 03 2016
Analysts Are Bullish on Valeant Dec 02 2016
Lifshitz & Miller Law Firm Announces Investigation of Georgetown Bancorp, Inc., Lattice... Dec 01 2016
ETFs with exposure to Mallinckrodt Plc : December 1, 2016 Dec 01 2016
Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016 Nov 30 2016
How Did Mallinckrodt’s Specialty Brands Perform in 2016? Nov 30 2016
Mallinckrodt Tops 4Q Earnings, Shares Tumble (MNK) Nov 30 2016
Mallinckrodt’s Revenue Growth in Fiscal 4Q16 Nov 30 2016
Mallinckrodt Plc :MNK-US: Earnings Analysis: Q4, 2016 By the Numbers : November 30, 2016 Nov 30 2016
Mallinckrodt To Present At BMO Capital Markets 2016 Prescriptions For Success Healthcare Conference Nov 30 2016
Edited Transcript of MNK earnings conference call or presentation 29-Nov-16 1:30pm GMT Nov 29 2016
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth Nov 29 2016
The Biggest Loser: Mallinckrodt Tumbles 9% Nov 29 2016
Mallinckrodt Earnings Top, But Stock Dives On Guidance Nov 29 2016
Mallinckrodt Beats Estimates, Issues Downbeat Guidance Nov 29 2016
Mallinckrodt Shares Tank, Despite Better-Than-Expected Earnings Nov 29 2016
What Do Analysts Have to Say about Mallinckrodt? Nov 29 2016
Mallinckrodt: Wait, I Thought It Was Good News?!?! Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)